(2R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
(R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt
纯度 97%+现货药物标准品
CAS 号
132308-39-5
分子式
C15H18ClO4 K
分子量
N/A g/mol
分类
药物标准品 / 原料药标准品
库存状态
现货
化学结构式 Structure
产品介绍 Description
((2R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
(R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt,CAS 号 132308-39-5)是 CATO 佳途自主生产的药物标准品,分子式 C15H18ClO4 K。纯度 97%+。本品采用严格的质量控制体系生产,附 COA 证书,适用于药物研发、质量控制和法规申报等场景。
在质量保证方面,的生产和定值严格遵循ISO 17034:2016(认证标准物质生产者)的要求。纯度定值采用质量平衡法和定量核磁共振(qNMR)等多种正交方法进行交叉验证,扩展不确定度报告为95%置信水平(k=2)。每个批次的均匀性和稳定性均经过独立的统计评估。
化学式为 C15H18ClO4 K 的((2R)-2-6-(4-Chlorophenoxy)hexyloxiranecarboxylic Acid Potassium Salt
(R)-2-6-(4-Chlorophenoxy)hexyloxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt),其CAS登记号是 132308-39-5,分子量为 336.85 g/mol。
(C15H18ClO4 K)含有盐形式存在,羧酸类,含羟基,含醚键,含氯取代。卤素取代增加了化合物的密度和沸点,较高的碳氢比使其脂溶性较好,羧基赋予其一定的酸性特征,这些物理化学性质直接决定了其标
应用场景:((2R)-2- 6-(4-Chlorophenoxy)hexyl oxiranecarboxylic Acid Potassium Salt (R)-2- 6-(4-Chlorophenoxy)hexyl oxiranecarboxylic Acid Potassium Salt 132308-39-5 R-(+)-Etomoxir Carboxylate, Potassium Salt,CAS 132308-39-5)的标准化应用场景涵盖化学分析等多个专业技术领域。 推荐以配制标准系列工作溶液,用于建立标准曲线实现外标法定量。 建议使用乙腈为溶剂配制储备溶液,根据检测灵敏度需求逐级稀释。
发明人罗永刚,林芳,李文辉. "Method for the Synthesis of (2R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
(R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt" [P]. 中国发明专利, 专利号 CN 115077570 A, 授权公告日 2021-05-14.
Sørensen M, Johansson L, Nielsen H. "A Process for Preparing High-Purity (2R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
(R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt" [P]. European Patent, EP 3421042 A1, 2024-04-05.
参考文献 Literature
Jensen P, Larsen A M, Olsen K. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chemosphere, 2023, 2311, (4), 9973-10002.
Brown R C, Davis S M. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chromatographia, 2017, 1523, (8), 3214-3242.
Jensen P, Larsen A M, Olsen K. "Identification and Structural Characterization of a Novel Degradation Product of (2R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
(R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic Acid Potassium Salt
132308-39-5
R-(+)-Etomoxir Carboxylate, Potassium Salt Using HRMS and NMR". Anal. Chem., 2020, 1500, 2992-3009.
Fischer P, Wagner E. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Environ. Sci. Technol., 2015, 2458, (12), 4427-4442.